Cycloserine fatty acid derivatives as prodrugs: Synthesis, degradation and in Vitro skin permeability

Chemical and Pharmaceutical Bulletin

Volumn 50, Issue 4, 2002, Pages 554-557

  Thorsteinsson, Thorsteinn ^a   Másson, Már ^a   Jarvinen, Tomi ^b   Nevalainen, Tapio ^b   Loftsson, Thorsteinn ^a  

^a UNIVERSITY OF ICELAND   (Iceland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Cycloserine; Hairless mouse skin; Hydrolysis; Permeability; Prodrug

Indexed keywords

4 AMINO 4,5 DIHYDROXYISOXAZOL 3 YLACETATE; 4 AMINO 4,5 DIHYDROXYISOXAZOL 3 YLLAURATE; 4 AMINO 4,5 DIHYDROXYISOXAZOL 3 YLOCTATE; 4 AMINO 4,5 DIHYDROXYISOXAZOL 3 YLOLEATE; CYCLOSERINE; FATTY ACID DERIVATIVE; N TERT BUTOXYCARBONYL 4 AMINO 4,5 DIHYDROXYISOXAZOL 3 YLACETATE; N TERT BUTOXYCARBONYL 4 AMINO 4,5 DIHYDROXYISOXAZOL 3 YLLAURATE; N TERT BUTOXYCARBONYL 4 AMINO 4,5 DIHYDROXYISOXAZOL 3 YLOCTANOATE; N TERT BUTOXYCARBONYL 4 AMINO 4,5 DIHYDROXYISOXAZOL 3 YLOLEATE; PRODRUG; UNCLASSIFIED DRUG; DRUG DERIVATIVE; FATTY ACID; TUBERCULOSTATIC AGENT;

ACIDITY; ALKALINITY; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; AQUEOUS SOLUTION; ARTICLE; CATALYSIS; CONTROLLED STUDY; DRUG DEGRADATION; DRUG PENETRATION; DRUG SYNTHESIS; ENZYME MECHANISM; FEMALE; HYDROLYSIS; IN VITRO STUDY; MOUSE; NONHUMAN; SKIN INFECTION; SKIN PERMEABILITY; ANIMAL; CHEMISTRY; HAIRLESS MOUSE; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PERMEABILITY; SKIN; SYNTHESIS;

ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; CYCLOSERINE; FATTY ACIDS; FEMALE; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, INBRED HRS; PERMEABILITY; PRODRUGS; SKIN;

EID: 0036547775     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.50.554     Document Type: Article

References (12)

1. Stewart J. T., Yoo G. S., J. Pharm. Sci., 77, 452-454 (1988).
2. Buhs R. P., Putter I., Ormond R., Lyons J. E., Chaiet L., Kuehl F. A., Wolf F. J., Trenner N. R., Peck R. L., Howe E., Hunnewell B. D., Downing G., Newstead E., Folkers K., J. Am. Chem. Soc., 77, 2344-2345 (1955).
3. Thompson L. T., Moskal J. R., Disterhoft J. F., Nature (London), 359, 638-641 (1992).
4. Howard J. C., McPherson J. C., Jr., Chuang A. H., J. Med. Chem., 17, 236-238 (1974).
5. Jensen N. P., Friedman J. J., J. Med. Chem., 23, 6-8 (1980).
6. Sprake S. A., Evered D. F., J. Pharm. Pharmacol., 31, 113-115 (1979).
7. Weaver J. D., Busch N. F., Stammer C. H., J. Med. Chem., 17, 1033-1035 (1974).
8. Másson M., Thorsteinsson T., Sigurdsson T. H., Loftsson T., Pharmazie, 55, 369-371 (2000).
9. Loftsson T., Thormar H., Ólafsson J. H., Gunnarssdóttir T. M., Hjaltason B., Gudmundsson G., Pharm. Pharmacol. Commun., 4, 287-291 (1998).
10. Ichiki Y., Hirose M., Akiyama T., Esaki C., Kitajima Y., Br. J. Dermatol., 136, 260-263 (1997).
11. Fasman G. D., "Practical Handbook of Biochemistry and Molecular Biology," CRC Press Inc., Florida, 1990.
12. NCCLS, "Methods for Dilution Antimicrobial Suseptibility Tests for Bacteria That Grow Aerobically; approved Standard-Fifth Edition," NCCLS document M7-A5 (ISBN 1-56238-394-9). NCCLS, Wayne, Pennsylvania 19087-1898, U.S.A., 2000.